Balance Sheet (Annual)

FMC / FMC Corp. Balance Sheet shows account balances for the company at points in time. Balance Sheet data includes Assets, Current Assets, Fixed Assets, Property, Plant and Equipment (PPE), Inventory, Intangibles, Liabilities, Current Liabilities, Debt, Capital Lease Obligations, Common Stock, Retained Earnings, Treasury Stock, and Shareholders Equity.

All numbers are times 1,000 except per share units.

2011 2012 2013 2014 2015 2016 2017
Assets
  Assets Current
    Cash And Cash Equivalents At Carrying Value 158,900 77,100 123,200 109,500 78,600 64,200 283,000
    Receivables Net Current 931,300 1,124,500 1,484,300 1,751,000 1,851,400 1,828,000 2,043,500
    Inventory Net 470,300 675,700 688,400 636,500 800,200 703,500 992,500
    Prepaid Expense And Other Assets Current 173,400 181,100 236,800 214,700 241,700 253,500 326,400
    Assets Of Disposal Group Including Discontinued Operation Current - - 198,300 0 0 - 7,300
    Assets Current 1,869,400 2,181,800 2,945,000 2,934,400 2,971,900 2,849,200 3,652,700
  Investments In Affiliates Subsidiaries Associates And Joint Ventures - 40,200 26,800 25,100 2,500 1,000 1,400
  Property Plant And Equipment Net 986,800 1,136,200 1,248,300 1,308,500 1,016,400 1,002,100 1,025,200
  Goodwill 225,900 294,400 389,400 352,500 776,100 777,500 1,198,900
  Intangible Assets Net Excluding Goodwill 187,300 215,700 272,300 246,900 837,000 793,400 2,631,800
  Other Assets Noncurrent 198,900 272,300 262,000 273,000 435,100 471,300 443,600
  Deferred Tax Assets Net Noncurrent 246,900 233,300 91,400 200,100 286,900 244,800 252,700
  Assets 3,743,500 4,373,900 5,235,200 5,340,500 6,325,900 6,139,300 9,206,300
Liabilities And Stockholders Equity
  Liabilities Current
    Debt Current 46,500 56,300 697,800 525,200 112,600 94,200 192,600
    Accounts Payable Current 458,300 443,200 475,200 433,500 403,600 355,400 714,200
    Customer Advances Current - 140,300 178,900 190,200 249,900 239,800 380,600
    Accrued Liabilities Current 186,200 192,000 307,000 438,800 337,600 374,900 497,700
    Accrued Customer Rebates 115,100 142,900 203,700 237,600 256,100 249,900 266,600
    Guarantees Of Vendor Financing 18,500 31,400 27,900 50,200 67,200 104,600 51,500
    Pension And Other Postretirement Defined Benefit Plans Current Liabilities - 21,300 12,700 12,700 6,400 7,100 5,700
    Accrued Income Taxes Current 15,500 32,900 35,300 22,200 19,900 12,300 99,200
    Liabilities Of Disposal Group Including Discontinued Operation Current - - 48,200 0 0 - 1,300
    Liabilities Current 919,900 1,135,400 1,986,700 1,910,400 1,453,300 1,438,200 2,209,400
  Long Term Debt Noncurrent 779,100 908,800 1,154,100 1,153,400 2,036,300 1,798,800 2,993,000
  Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent 368,700 375,800 57,800 238,700 194,200 140,400 59,300
  Accrued Environmental Loss Contingencies Noncurrent 213,300 200,200 175,200 209,900 281,800 306,400 346,200
  Deferred Tax Liabilities Noncurrent - - 73,100 51,300 173,200 167,400 173,200
  Other Liabilities Noncurrent 116,800 154,500 216,200 212,800 278,800 295,100 718,100
  Commitments And Contingencies - - - - - - -
  Stockholders Equity
    Preferred Stock Value 0 0 0 0 0 0 0
    Common Stock Value 9,300 18,600 18,600 18,600 18,600 18,600 18,600
    Additional Paid In Capital Common Stock 463,800 481,900 448,300 401,900 417,700 418,600 450,700
    Retained Earnings Accumulated Deficit 2,176,200 2,536,500 2,757,300 2,984,500 3,385,000 3,505,500 3,952,400
    Accumulated Other Comprehensive Income Loss Net Of Tax -390,000 -408,900 -201,900 -375,800 -457,300 -478,400 -240,300
    Treasury Stock Value 1,018,700 1,147,800 1,502,500 1,498,700 1,498,300 1,506,600 1,499,600
    Stockholders Equity 1,240,600 1,480,300 1,519,800 1,530,500 1,865,700 1,957,700 2,681,800
    Minority Interest 63,500 74,500 52,300 33,500 42,600 35,300 25,300
    Stockholders Equity Including Portion Attributable To Noncontrolling Interest 1,304,100 1,554,800 1,572,100 1,564,000 1,908,300 1,993,000 2,707,100
  Liabilities And Stockholders Equity 3,743,500 4,373,900 5,235,200 5,340,500 6,325,900 6,139,300 9,206,300

Peers - Chemicals And Allied Products (28)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 302491303